News Quantified

AKTX – akari therapeutics plc - american depositary shares (US:NASDAQ)

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

1/26

08:45 am

aktx

Low

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics to Present at the 2026 Biotech Showcase

Akari Therapeutics (NASDAQ:AKTX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.00 price target on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}